Authors: Stéphanie Tellier Karine Brochard Arnaud Garnier Flavio Bandin Brigitte Llanas Vincent Guigonis Mathilde Cailliez Christine Pietrement Olivier Dunand Sylvie Nathanson Aurélia BertholetThomas Lydia Ichay Stéphane Decramer
Publish Date: 2013/01/23
Volume: 28, Issue: 6, Pages: 911-918
Abstract
This was a retrospective multicenter study of 18 children treated with RTX for SDNS with a mean followup of 32 years RTX was introduced because of side effects or relapses during therapy with immunosuppressive agents The children received one to four infusions of RTX during the first course of treatment and subsequent infusions were given due to CD19cell recovery CD19 1 54 of children or relapse 41 as well as systematically 5 Treatment with RTX maintained sustained remission without relapse in 22 of patients and increased the duration of remission in all other patients The time between two successive relapses was 9 months in the absence of retreatment and 245 months when infusions were performed at the time of CD19cell recovery At the last followup 445 of patients were free of oral drug therapy Of those still receiving oral drugs all doses had been decreased No serious adverse events occurred
Keywords: